Abstract
Introduction: In addition to their lipid-lowering action, it has been demonstrated that statins can exert direct anti-inflammatory effects. We investigated the effect of preoperative statin therapy on systemic inflammatory markers and myocardial NF-κB inhibitor IκB-α after cardiac surgery. Methods: Thirty-six patients undergoing elective coronary artery bypass grafting with cardiopulmonary bypass (CPB) with cardioplegia were divided into two groups (statin group, n = 18; control group, n = 18). Plasma concentrations of pro-inflammatory cytokines (tumor necrosis factor α [TNFα], interleukin [IL]-6, IL-8) and anti-inflammatory IL-10 were measured before and 1, 4, 10, and 24 hours (h) after CPB. Phosphorylated IκB-α/total IκB-α ratio was assessed before and after CPB in right atrial biopsies. Results: Baseline and operative data did not differ between groups. Statin therapy was associated with lower preoperative low-density lipoprotein levels compared to control (73 ± 6 vs. 92 ± 6 mg/dL; p = 0.03). Release of IL-6 was attenuated in the statin group at 4 h (2270 ± 599 vs. 5120 ± 656 pg/ml; p < 0.01) and 10 h (1295 ± 445 vs. 3116 ± 487 pg/ml; p < 0.05) compared to the control group. IL-10 increased after surgery in both groups (p < 0.05), but was higher in the statin group at 1 h (66 ± 15 vs. 26 ± 16 pg/mL; p < 0.01). Phosphorylated IκB-α/total IκB-α ratio before CPB did not differ between groups, but was elevated after CPB in both groups (p < 0.05), indicating enhanced degradation of IκB-α. Statin therapy had no effect on TNFα and IL-8. Conclusions: Preoperative statin therapy attenuates the release of pro-inflammatory IL-6 and up-regulates anti-inflammatory IL-10 after cardiac surgery with cardioplegia, but fails to inhibit phosphorylation of myocardial IκB-α.
Key words
Statins - inflammatory response - cytokines - cardiovascular surgery
References
-
1
Christenson J T.
Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease.
Am J Cardiol.
2001;
88
896-899
-
2
Knatterud G L, Rosenberg Y, Campeau L. et al .
Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.
Circulation.
2000;
102
157-165
-
3
Pan W, Pintar T, Anton J, Lee V V, Vaughn W K, Collard C D.
Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery.
Circulation.
2004;
110
45-49
-
4
Schonbeck U, Libby P.
Inflammation, immunity, and HMG‐CoA reductase inhibitors: statins as antiinflammatory agents?.
Circulation.
2004;
109
18-26
-
5
Brull D J, Sanders J, Rumley A, Lowe G D, Humphries S E, Montgomery H E.
Statin therapy and the acute inflammatory response after coronary artery bypass grafting.
Am J Cardiol.
2001;
88
431-433
-
6
Lazar H L, Bao Y, Zhang Y, Bernard S A.
Pretreatment with statins enhances myocardial protection during coronary revascularization.
J Thorac Cardiovasc Surg.
2003;
125
1037-1042
-
7
Hennein H A, Ebba H, Rodriguez J L. et al .
Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization.
J Thorac Cardiovasc Surg.
1994;
108
626-635
-
8
Onai Y, Suzuki J, Kakuta T. et al .
Inhibition of Ikappa B phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury.
Cardiovasc Res.
2004;
63
51-59
-
9
Valen G, Paulsson G, Vaage J.
Induction of inflammatory mediators during reperfusion of the human heart.
Ann Thorac Surg.
2001;
71
226-232
-
10
Christman J W, Lancaster L H, Blackwell T S.
Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy.
Intensive Care Med.
1998;
24
1131-1138
-
11
Dichtl W, Dulak J, Frick M. et al .
HMG‐CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Arterioscler Thromb Vasc Biol.
2003;
23
58-63
-
12
Chello M, Mastroroberto P, Patti G. et al .
Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass.
Heart.
2003;
89
538-543
-
13
Liakopoulos O J, Mühlfeld C, Koschinsky M, Coulibaly M O, Schoendube F A, Dörge H.
Progressive loss of myocardial contractile function despite unimpaired coronary blood flow after cardiac surgery.
Basic Res Cardiol.
2005;
100
75-83
-
14
Wan S, LeClerc J L, Vincent J L.
Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation.
Ann Thorac Surg.
1997;
63
269-276
-
15
Massy Z A, Kim Y, Guijarro C, Kasiske B L, Keane W F, O'Donnell M P.
Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin.
Biochem Biophys Res Commun.
2000;
267
536-540
-
16
Florens E, Salvi S, Peynet J. et al .
Can statins reduce the inflammatory response to cardiopulmonary bypass? A clinical study.
J Card Surg.
2001;
16
232-239
-
17
Sadeghi M M, Collinge M, Pardi R, Bender J R.
Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein.
J Immunol.
2000;
165
2712-2718
-
18
Hölschermann H, Schuster D, Parviz B, Haberbosch W, Tillmanns H, Muth H.
Statins prevent NF-κB transactivation independently of the IKK-pathway in human endothelial cells.
Atherosclerosis.
2006;
185
240-245
-
19
Rao S, Porter D C, Chen X, Herliczek T, Lowe M, Keyomarsi K.
Lovastatin mediated G1 arrest is through inhibition of the proteosome, independent of hydroxymethyl glutaryl-CoA reductase.
Proc Natl Acad Sci USA.
1999;
96
7797-7802
-
20
Ludwig A, Friedel B, Metzkow S. et al .
Effect of statins on the proteosomal activity in mammalian endothelial and vascular smooth cell muscle cells.
Biochem Pharmacol.
2005;
70
520-526
Dr. Oliver J. Liakopoulos
Klinik für Thorax-, Herz- und Gefäßchirurgie
Herzzentrum Göttingen, Georg-August-Universität Göttingen
Robert-Koch-Straße 40
37099 Göttingen
Germany
Telefon: + 49551396001
Fax: + 49 551 39 60 02
eMail: oliver@liakopoulos.de